Clene’s CNM-Au8: A Promising Candidate in ALS Treatment with Buy Rating from Justin Walsh

JonesTrading analyst Justin Walsh maintained a Buy rating on Clene yesterday and set a price target of $30.00.

Justin Walsh has given his Buy rating due to a combination of factors that highlight Clene’s potential in the ALS treatment landscape. The company’s CNM-Au8 asset is positioned as a promising candidate in addressing the unmet needs within the current ALS treatment options. This is particularly significant given the limited efficacy of existing therapies and the withdrawal of some treatments from the market.
Furthermore, the ongoing advancements in late-stage therapeutic agents, including mutation-targeted antisense oligonucleotides and cell therapies, underscore the innovative approach Clene is taking. The strategic positioning of CNM-Au8 within this evolving landscape, coupled with its potential to offer a novel treatment pathway, supports the optimistic outlook and the Buy rating assigned by Justin Walsh.